TP53 and prostate carcinoma: For instance, germline mutations such as BRAC1/BRAC2 and somatic mutations such as tumour protein p53 (p53) are notably associated with increased risk of prostate cancer progression and poor survival outcomes following treatments such as radical prostatectomy, androgen deprivation chemotherapy, or radiotherapy [223,227,228,229,230,231].